Key result
Adult acute leukemia carries a ~1.5% incidence of symptomatic VTE.
Observational (n=1,461)
Yes
Multi-center study evaluates treatment and outcomes of venous thromboembolism in high-risk acute leukemia patients, highlighting clinical implications.
In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. The intention was to find as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.5%. VTE occurred during chemotherapy in 17/22 (77.2%) cases, mainly (14/17, 82.3%) during the induction phase. Treatment of acute VTE was based on Low Molecular Weight Heparin (LMWH) at full dosage for the first month from diagnosis and reduced dosage (75%) for the following months.
No takes yet. Share an insight, caveat, or question.
Napolitano et al. (2015) conducted an observational in Acute leukemia and symptomatic venous thromboembolism (n=1,461). Acute leukemia was evaluated on Absolute incidence of symptomatic venous thromboembolism (VTE). Acute leukemia in adults was associated with a 1.5% absolute incidence of symptomatic venous thromboembolism, which was primarily managed with Low Molecular Weight Heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: